Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 15,301–15,400 of 15,747
Lee, H. S., & Kim, K. S. (2022) · Clinical Ultrasound · doi:10.18525/cu.2022.7.2.90
“08%로 COVID-19가 두 가지 다른 유행병보 다 현저히 낮으나 전파율은 상당히 높다[2-5].”
Synthesis and optimization of ionizable lipids for RNA delivery
Wu, B., Lu, X., Padilla, M. S., Dharmesh, E., Xu, Y., Mitchell, M. J., & Han, X. (2026) · Chem · doi:10.1016/j.chempr.2026.103244 · Cited by 1
COVID-19 in patients with inflammatory bowel diseases: Characteristics and guidelines
Taxonera, C., & López-García, O. N. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-18703-2.00022-0
Gokani, K., Taylor, A. E., Packham, A., Musabyimana, J. P., Shema, H., Mutabaruka, A., Roche, S., Takwoingi, Y., Claudine, U., Nyombayire, J. M., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2025-102898 · Cited by 1
The potential public health consequences of “mRNA vaccine stigmatization” in the US
Motta, M. (2026) · Politics and the Life Sciences · doi:10.1017/pls.2026.10027
Geller, M. (2020) · Arquivos de Asmas Alergia e Imunologia · doi:10.5935/2526-5393.20200057
Conlon, C. P., & Firth, J. D. (2020) · doi:10.1093/med/9780198746690.003.0650_update_003
Portillo-Blanco, A., Díez, J. R., Barrutia, O., Garmendia, M. C., & Guisasola, J. (2022) · Redalyc (Universidad Autónoma del Estado de México)
Graf, N., Bayerl, J., & Schmidt, B. (2025) · Infection · doi:10.1007/s15010-025-02544-6
“S (Johnson & Johnson) excluded patients undergoing tumour therapy [2–5].”
Nanotechnology-Enhanced Vaccines for Respiratory Infections: Opportunities and Challenges
Wang, K., Jiang, Y., & Zhou, Y. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s612148
A Fatal Case of COVID-19 Pneumonia in a Fully Vaccinated Heart Transplant Recipient
Belur, A. D., Otero, D., & Matos, C. D. (2022) · The University of Louisville Journal of Respiratory Infections · doi:10.55504/2473-2869.1236
“[1] An interim analysis of the phase III trial showed that the BNT162b vaccine conferred 95% protection against infection in persons 16 years of age or older who had received a two-dose regimen.[2] However, key exclusion criteria for this study included a history of treatment with immunosuppressive therapy or diagnosi…”
BackgroundMethodPeña, Á., Broset, E., Lucía, E. G., García-Latorre, L., Navarro, V., Matute, C., Gallego-Lleyda, A., Alejo, T., Romanos, E., García, A., et al. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18040472
County-Level Vaccination Coverage and Rates of COVID-19 Cases and Deaths in the United StatesPreprint
McLaughlin, J. M., Khan, F. L., Pugh, S. J., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3908476
Selvaraj, P., Stauft, C. B., Liu, S., Sangare, K., & Wang, T. T. (2025) · npj Viruses · doi:10.1038/s44298-025-00125-w
Pharmaceuticals/biotechnology—engineered proteins, vaccines, DNA vaccines
Graves, J. L. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-822105-1.00009-3
Malo-Castillo, J., Jiménez-Álvarez, H., Ludeña-Meléndez, V., Castro, S. S. M., Rodríguez-Esquivel, S. E., Ishikawa-Arias, P., Terrones, C., Chavarría, L. L., Linares-Reyes, E., & Failoc‐Rojas, V. E. (2024) · Vaccines · doi:10.3390/vaccines12040400
“…variables included in the adjustment were age, sex, homologous or heterologous vaccination, presence of comorbidities, history of previous COVID-19 infection, and simultaneous vaccination against influenza according to epidemiological criteria theoretical background found in the literature [15,16].”
MethodResultResearch and Development of HFMD Vaccines
Zhao, H. (2024) · Springer eBooks · doi:10.1007/978-981-99-9660-5_6
Development of the COVID-19 (SARS-CoV-2) mRNA Vaccines: Translational Medicine at its Best
García, B., Padgett, K., & Russo, J. L. A. (2022) · Journal of Medical - Clinical Research & Reviews · doi:10.33425/2639-944x.1261
“The incidence of serious adverse events was low and was similar in the vaccine and placebo groups [21].”
BackgroundPortilho, M. M., Tosta, S. F. D. O., Pellizzaro, M., dos Anjos, R. O., de Oliveira, E. C., de Santana, P. D. S. N., Moreira, P. S. D. S., Jacob-Nascimento, L. C., Souza, M. M. D. S., Mothé, D. B., et al. (2026) · Immunity Inflammation and Disease · doi:10.1002/iid3.70441
Functionalized Nanomaterials for Drug Delivery
George, N., Janiyani, K., Ogoe, M., Gupta, A., Safo, K. K., Singh, H., & Pandya, S. R. (2025) · Series in bioengineering · doi:10.1007/978-981-95-0457-2_3 · Cited by 2
Pulmonary embolism after COVID-19 vaccination
Sheehan, K. N., & Zhao, D. X.-M. (2021) · Journal of Case Reports and Images in Medicine · doi:10.5348/100064z09ks2021cs
nSARS-CoV-2 and COVID-19 Pandemic: From Emergence to Vaccination
Shahid, I. (2022) · Dr Sulaiman Al Habib Medical Journal · doi:10.1007/s44229-022-00006-x
Salman, H. A., Hussin, A. M., Hassan, A. H., Sabbah, H. A., & Al-Khafaji, K. (2023) · Arab Gulf Journal of Scientific Research · doi:10.1108/agjsr-04-2023-0144
Belayneh, E. K., Leulseged, T. W., Teklu, B. S., Tewodros, B. H., Megiso, M. Z., Weldesenbet, E. S., Berhanu, M. F., Shaweno, Y. S., & Hailu, K. T. (2024) · Cureus · doi:10.7759/cureus.67719
Accuracy of COVID-19-Like-Illness Diagnoses in Electronic Health Record Data (Preprint)Preprint
Rao, S., Bozio, C. H., Butterfield, K. A., Reynolds, S. B., Reese, S. E., Ball, S. W., Steffens, A., Demarco, M., McEvoy, C., Thompson, M. G., et al. (2022) · doi:10.2196/preprints.39231
SARS-CoV-2 infection in a fully vaccinated case with newly diagnosed breast cancer: a case reportPreprint
Vandone, A. M., Alessio, M., Prati, V., et al. (2021) · Qeios · doi:10.32388/3sgegm
Roederer, A. L., Li, C. J., Lim, E. Y. P., et al. (2025) · medRxiv · doi:10.1101/2025.03.01.25323010
“The first generation of COVID vaccines 6–9 were based on the Wuhan strain of SARS-CoV-2 spike protein, containing 2 proline-stabilizing mutations that were previously used to stabilize other related spike proteins 10 .”
Maister, A., Zakai, T. G., Fried, C., Petersiel, N., Mousa, A., Bishop, B., Korytny, A., Zeidan, M., Rozenberg, G., & Neuberger, A. (2026) · Tropical Diseases Travel Medicine and Vaccines · doi:10.1186/s40794-025-00286-9
Liver injury after COVID-19 vaccination: Current status and future perspectives
Sato, K. (2026) · World Journal of Hepatology · doi:10.4254/wjh.v18.i5.116542
Morio, R., Takazono, T., Morimoto, S., Ashizawa, N., Hirayama, T., Yoshida, M., Takeda, K., Hirano, K., Ide, S., Iwanaga, N., et al. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.128861
Modeling the Risk of In-Person Instruction During the COVID-19 Pandemic
Liu, B. S., Zhang, Y., Henderson, S. G., Shmoys, D. B., & Frazier, P. I. (2024) · INFORMS Journal on Applied Analytics · doi:10.1287/inte.2023.0076 · Cited by 3
The Nature of Chronic Diseases and Mental Disorders
Fuller, J. (2025) · Oxford University Press eBooks · doi:10.1093/9780190066178.003.0006
Filon, F. L., Rui, F., Ronchese, F., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-803215/v1
Ilkov, O., Kolesnyk, P., Русановська, О., Mykyta, T., Sabov, O., & Kaliy, V. V. (2022) · Family Medicine · doi:10.30841/2307-5112.1-2.2022.260498 · Cited by 1
Wilhelm, M. (2021) · Pharmacy Today · doi:10.1016/j.ptdy.2021.07.022
Autosomal and X-Linked Degenerative Ataxias: From Genetics to Promising Therapeutics
Hadji, A., Louit, A., Roy, V., Blais, M., Berthod, F., Gros‐Louis, F., & Dupré, N. (2023) · Contemporary clinical neuroscience · doi:10.1007/978-3-031-24345-5_5 · Cited by 1
N6-Adenosine Methylation of a Single Site in SARS-CoV-2 5′-UTR Promotes TranslationPreprint
Aly, A., Scott, G., Calderon, M., & Haghighi, A. P. (2026) · eLife · doi:10.7554/elife.111963.1 · Cited by 1
Fan, C., Cohen, A. A., Dam, K.-M. A., Rorick, A. V., Fils, A.-C. I. P., Yang, Z., Gnanapragasam, P. N. P., Segovia, L. N., Huey‐Tubman, K. E., Moon, W. J., et al. (2025) · eLife · doi:10.7554/elife.108959.1 · Cited by 1
Ryabtseva, O. A., Tsygankov, P. V., Shlyk, S. V., Kharseeva, G. G., & Владимировна, Ч. А. (2023) · Epidemiology and Vaccinal Prevention · doi:10.31631/2073-3046-2023-22-1-82-88
Engineering stress-tolerant mammalian embryos via a functional trehalose transporter
Shibasaki, I., Yoshimura, K., Kasai, T., et al. (2026) · Reproduction · doi:10.1093/reprod/xaag013
(2022) · doi:10.1101/2022.06.23.22276809 · Cited by 17
Anonymous (2021) · Journal de Pédiatrie et de Puériculture · doi:10.1016/j.jpp.2021.06.001
Nebane, N. M., Reece, A., Rasmussen, L. A., et al. (2025) · SLAS DISCOVERY · doi:10.1016/j.slasd.2025.100246
Is Emergency Surgery Back to Pre-Covid-19 Era? Our Cohort Study
Pavone, G., Gerundo, A., Pacilli, M., et al. (2022) · Chirurgia · doi:10.21614/chirurgia.2796
“There are different types of vaccines, including mRNA, vector and inactivated vaccines, and population studies have demonstrated their success (13-17).”
BackgroundKim, M. J., Prieto‐Merino, D., Nicholas, J. M., Allen, L., Bastawrous, A., & Macleod, D. (2026) · BMC Medical Research Methodology · doi:10.1186/s12874-026-02780-w
“When one arm performed 2% better, adaptive trials had more than 98.5% probability in correctly adopting the superior arm with a median sample size of 6,100 [IQR 3,100; 10,600].”
InfluentialSharon, N. Z., Maymon, R., Svirsky, R., Novikov, I., Cuckle, H., & Levtzion‐Korach, O. (2024) · Research Square · doi:10.21203/rs.3.rs-3759326/v1 · Cited by 1
Benucci, M., Cioffi, E., Gobbi, F. L., Cassarà, E. A. M., Terenzi, R., Russo, E., Grossi, V., Lari, B., Infantino, M. G., & Manfredi, M. (2026) · Antibodies · doi:10.3390/antib15020024
“The most frequently reported adverse effects include local injection-site reactions and systemic symptoms such as fatigue, headache, myalgia, arthralgia, fever, and chills [8].”
Association between mRNA COVID-19 vaccination and myocarditis
Tomkins, A. M., & Stiles, M. K. (2022) · New Zealand Medical Student Journal · doi:10.57129/uzxq3935
Farrelly, C. (2026) · Oxford University Press eBooks · doi:10.1093/9780197830062.003.0009
Yao, Y., Yang, Y., Wu, Q., Liu, M., Bao, W., Wang, Q., Cheng, M., Chen, Y., Cai, Y., Zhang, M., et al. (2025) · European journal of medical research · doi:10.1186/s40001-024-02240-5 · Cited by 1
COVID-19 Vaccines: Fabrication Techniques and Current Status
Kaur, L., Mahajan, A., Singh, G., Dhawan, R. K., Singh, L., & Kaur, A. (2021) · Coronaviruses · doi:10.2174/2666796702666210728150704
From the Masters: How RNA drugs will transform vascular medicine
Cooke, J. P. (2025) · Vascular Medicine · doi:10.1177/1358863x251323275
A single BNT162b2 dose protects against SARS-CoV-2: A case report of a family cluster of COVID-19.
Morales-Contreras, J. A., Ruiz-Quiñones, J. A., Roblero-Hernández, A., Horemheb-Rubio, G., & Suárez-Méndez, S. (2021) · REVISTA BIOMÉDICA · doi:10.32776/revbiomed.v32i3.912
“However, during the time interval between the first and second doses, the observed vaccine efficacy against COVID-19 was 52% (10).”
BackgroundAlshaikh, R. A., Cronin, D. J., Hughes, D. A., & O’Driscoll, C. M. (2026) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2026.107652
Azhar, L. E., Alsaieedi, A., AlEissa, M. M., Baroom, H. A., Alghoraibi, A. H., Alzahrani, K. S., & Azhar, E. I. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1853635
Reply to “How important is the second dose of the COVID-19 mRNA vaccine?”
Shaker, M. S., Phillips, E. J., Blumenthal, K. G., Abrams, E. M., Banerji, A., Oppenheimer, J. J., Leek, T. K. V., Mack, D. P., Wickner, P. G., Singer, A. G., et al. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.03.016
Comparing Vaccination Strategies in Canada Under Different AssumptionsPreprint
Ruse, T. (2021) · medRxiv · doi:10.1101/2021.03.02.21252761
Sung, M., Kim, Y. S., Cho, C. Y., Son, Y., Kim, D. W., & Lee, S. H. (2024) · Vaccines · doi:10.3390/vaccines12101190 · Cited by 2
“As the severity of the pandemic became evident, global efforts quickly prioritized the development of vaccines [18–21].”
BackgroundKasai, T., Yamada, M., Funaki, T., Tao, C., Myojin, S., Aiba, H., Matsui, T., Ogimi, C., Miyake, K., Ueno, S., et al. (2024) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2024.12.008
Romano, C. P., Esposito, S., Donnarumma, G., & Marrone, A. (2021) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2021.09.023
The puzzle of scientific disagreement
Cocchiaro, M. Z., & Trpin, B. (2025) · European Journal for Philosophy of Science · doi:10.1007/s13194-025-00662-4
“Similarly, in the mRNA vaccine debate, some researchers, like Polack et al. (2020), highlight the promising short-term safety and efficacy of these vaccines, while others, such as Ioannidis (2021), consider their decreased efficacy due to the greater exposure of the vaccinated: the disagreement…”
Betting on Biology: Rethinking Probability as the Currency of Risk in Biotechnology Portfolios
Krishna, R. (2026) · The AAPS Journal · doi:10.1208/s12248-026-01290-3
“The clinical and commercial success of mRNA vaccines developed, as an example, by Moderna and BioN-Tech transformed perceptions of modality risk within a short timeframe (12, 13).”
Spiliopoulou, P., van Rensburg, H. J. J., Avery, L. M., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2214679/v1
Saiki, S., Kuroiwa, M., Hashimoto, K., Nakajima-Yoshida, H., Susai, N., Kato, H., Hamana, S., Ishida, S., Nikaido, E., Toyota, T., et al. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.129177
Novel approaches to immuno-oncology
Chen, R., & Su, F. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-14064-8.00047-3
Palacka, P., Marušáková, E., Rejleková, K., Svobodova, A., Skokanová, L., Vulganova, M., & Obertová, J. (2025) · Biomedical Reports · doi:10.3892/br.2025.1998
COVID-19 mRNA vaccine: safety and situation of clinical application
Niu, G. (2022) · International Conference on Biomedical and Intelligent Systems (IC-BIS) · doi:10.1117/12.2660328
“ANG (1-7) can effectively prevent damage caused by inflammation and high blood sugar and can improve the vitality of insulin to prevent heart failure and stroke.”
BackgroundMucosal Immune Response after the Booster Dose of the BNT162b2 COVID-19 VaccinePreprint
Azzi, L., Gasperina, D. D., Veronesi, G., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4131248
Miyamae, C., Isozaki, Y., Tsumoto, K., & Tomita, M. (2025) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2025.130822
Zhai, L., Zhuang, M., Wong, H. K., Lin, C., Zhang, J., Bao, G., Zhang, Y., Xu, S., Luo, J., Yuan, S., et al. (2024) · medRxiv · doi:10.1101/2023.12.27.23299358
COVID-19 Vaccine Hesitancy in Oncology Patients
Sardina, I. M. V., Kumar, M., & Joseph, R. P. (2021) · Bengal Journal of Cancer · doi:10.4103/bjoc.bjoc_26_21
Aty, Y. M. V. B., Selasa, P., Molina, M. B., et al. (2022) · JURNAL INFO KESEHATAN · doi:10.31965/infokes.vol20.iss1.588
Hartley, G. E., Edwards, E. S. J., Varese, N. P., Boo, I., Aui, P. M., Bornheimer, S. J., Hogarth, P. M., Drummer, H. E., O’Hehir, R. E., & van Zelm, M. C. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.08.03.502703
A review of the latest research and development of the pathogenesis and treatment of COVID-19
Ding, Y. (2023) · Theoretical and Natural Science · doi:10.54254/2753-8818/22/20231004
das Chagas, R. R., Freitas, H. R., & Cardozo, S. V. (2024) · medRxiv · doi:10.1101/2024.09.08.24313185 · Cited by 1
Lundstrom, K. H. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818731-9.00137-3
Dumas, P., Bertoli, S., Bonmati, C., et al. (2022) · Leukemia Research · doi:10.1016/j.leukres.2022.106901
Dimitrov, G., Kalinov, K., & Valkov, T. (2024) · Biotechnology & Biotechnological Equipment · doi:10.1080/13102818.2024.2359003
“Numerous prospective studies and retrospective analyses have consistently demonstrated the effectiveness of the COVID-19 vaccines in reducing premature mortality rates [8–10].”
Baltu, D., Şükür, E. D. K., Ozturk, T. T., et al. (2024) · Klinische Pädiatrie · doi:10.1055/a-2319-2648
“The effectiveness and safety of the COVID-19 vaccine in children have been demonstrated in clinical trials [23, 24].”
BackgroundAkaluc bioluminescence offers superior sensitivity to track in vivo dynamics of SARS-CoV-2 infectionPreprint
Tamura, T., Ito, H., Torii, S., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.12.561993
Sousa, J. M. D. (2026) · Biophysical Chemistry · doi:10.1016/j.bpc.2026.107651
Mohammed, N. A., Hassan, Z. F., Sabri, G., et al. (2024) · Annals of the College of Medicine Mosul/Annals of the College of Medecine · doi:10.33899/mmed.2023.142494.1223
Montagud, A. C., Llenas‐García, J., Moragues, R., Pérez-Bernabeu, A., Pertegal, M. J. A., Gómez, F. J. G., Serna, A. M. G., Morante, H. G., Caballero, P., & Tuells, J. (2024) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2024.02.013 · Cited by 1
Bathula, N. V., Soriano, S. K. V., Huang, C., Jan, E., Sagan, S. M., & Blakney, A. K. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.07.004 · Cited by 1
A Hybrid SEIHCRDV-UKF Model for COVID-19 Prediction. Application on real-time dataPreprint
Papageorgiou, V. Ε., & Tsaklidis, G. M. (2022) · Research Square · doi:10.21203/rs.3.rs-1816184/v2
Jamous, Y. F. (2026) · Pandemics · doi:10.3390/pandemics1020008 · Cited by 2
“Lipid nanoparticles (LNPs), in particular, have been central to the delivery of nucleic acids, including those in mRNA-based COVID-19 vaccines, which represented an important advancement in vaccine nanotechnology [13–15].”
Roxana, P., Duma, M., Szep, M., et al. (2021) · International Journal of Innovative Research in Medical Science · doi:10.23958/ijirms/vol06-i10/1233
Qian, J. (2023) · International Conference on Modern Medicine and Global Health (ICMMGH) · doi:10.1117/12.2692454
“Recently, the development of COVID vaccines, such as Pfizer-BioNTech's BNT162b2 and Moderna's mRNA-1273, also utilized such technique as a drug delivery platform [5, 6].”
MethodGrice, J. W., Barrett, P. T., & Martin, M. (2025) · Open Journal of Applied Sciences · doi:10.4236/ojapps.2025.159178
Cot, C. (2021) · theses.fr (ABES) · doi:10.70675/32baf057zb898z40b8zbf61z75835e8c639c · Cited by 1
The lapse of federal COVID-19 funding: implications for health equity
Kobayashi, K., Miller-Fitzwater, A., Grier, C., Montez, K. G., Shah, S. I., Raphael, J. L., Patel, M. S., Keller, D., Chamberlain, L. J., Cheng, T. L., et al. (2023) · Pediatric Research · doi:10.1038/s41390-023-02487-4
“Both vaccines have been proven safe and effective in preventing SARSCoV-2 infection and serious illness.(9,10) Regarding recently emerging strains, BNT162b2 (Pfizer-BioNTech) is up to 60.”
BackgroundIs it safe to be pregnant during the COVID-19 pandemic?
Prabhu, M. (2021) · OBG Management · doi:10.12788/obgm.0063
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.